- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05906537
SKB410 for Injection in Solid Tumors
June 13, 2023 updated by: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB410 for Injection in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB410 for injection in patients with advanced solid tumors.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, PK profile, and anti-tumor efficacy of SKB410 for injection in patients with advanced solid tumors.This study consists of two phases, Phase Ia and Phase Ib: Phase Ia is a dose escalation phase, and subjects with advanced solid tumors will be enrolled to receive SKB410 for Injection; Phase Ib is a dose expansion phase, and the expansion dose(s) for specific cancer will be determined based on Phase Ia result.
Study Type
Interventional
Enrollment (Estimated)
276
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shen Lin, MD
- Phone Number: 86-010-88196561
- Email: doctorshenlin@sina.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- At the time of signing the ICF: age ≥ 18 years, male or female.
- Phase Ia: subjects with histologically or cytologically confirmed locally advanced or metastatic solid tumors who have failed/are intolerant/ineligible to or do not have standard therapy, and have at least one measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
- Expected survival ≥ 3 months.
- Subjects with adequate organ and bone marrow function confirmed by laboratory results within 3 days prior to the first dose.
- Subjects of childbearing potential (male or female) must use effective medical contraception during the study until 6 months after the last dose.
- Ability to understand and willingness to sign ICF, and will be able to comply with the protocol-specified visits and relevant procedures.
Exclusion Criteria:
- Has received anti-tumor therapy, including chemotherapy, targeted therapy, tumor immunotherapy, and traditional Chinese medicinal products with anti-tumor indications, within 4 weeks prior to the first dose or within 5 half-lives of known drugs (whichever is shorter).
- Has received radiotherapy within 4 weeks prior to the first dose.
- Has had major surgery within 4 weeks prior to the first dose.
- Has received strong cytochrome P450 (CYP3A4) inhibitors or inducers (see Annex 4) within 2 weeks prior to the first dose or within 5 half-lives of known drug, whichever is longer.
- Has not recovered to normal or ≤ Grade 1 from any AE and/or complication due to any prior therapy (except alopecia or pigmentation).
- Has known history of allergy to any component of SKB410 or other monoclonal antibodies.
- Has a known previous or concurrent other malignancies within 5 years prior to signing the ICF.
- Presence of active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Has active autoimmune disease with systemic therapy or immunosuppressive therapy within 2 years prior to signing the ICF.
- Has uncontrolled or severe cardiovascular disease.
- Has uncontrolled systemic diseases.
- Presence of clear neurological or psychiatric disorder.
- Has active infection requiring systemic.
- Has human immunodeficiency virus (HIV) infection; has any active viral hepatitis.
- Pregnant or lactating.
- Has prior autologous/allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
- Has any other conditions such as medical history, treatment and laboratory abnormalities that may confound the study results, interfere with the subject's compliance, or impair the subject's interests, as assessed by the investigator or the sponsor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase Ia (Dose Escalation Phase)+Phase Ib (Dose Expansion Phase)
Several dose levels are planned for Phase1a and administered every 2 weeks.The dose of SKB410 for injection in Phase 1b is selected based on the Phase 1a.
|
SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase Ia :To assess the safety and tolerability of SKB410 in subjects with advanced solid tumors.
Time Frame: From data of initial dose until up to 28 days for treatment
|
Incidence of Dose Limiting Toxicities,the MTD of SKB410
|
From data of initial dose until up to 28 days for treatment
|
Phase Ib:ORR
Time Frame: through study completion, an average of 2 years
|
ORR based on RECIST v1.1.
|
through study completion, an average of 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR, DCR, DOR, PFS, OS
Time Frame: through study completion, an average of 2 years
|
|
through study completion, an average of 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 30, 2023
Primary Completion (Estimated)
June 30, 2025
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
May 16, 2023
First Submitted That Met QC Criteria
June 13, 2023
First Posted (Estimated)
June 16, 2023
Study Record Updates
Last Update Posted (Estimated)
June 16, 2023
Last Update Submitted That Met QC Criteria
June 13, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SKB410-I-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
Clinical Trials on SKB410 for injection
-
Bio-Thera SolutionsNot yet recruiting
-
Shanghai Gebaide Biotechnology Co., Ltd.UnknownNon-small-cell Lung Cancer (NSCLC) Stage IVChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
AstraZenecaCompletedHealthy Elderly | Mild-Moderate Alzheimer's DiseaseUnited States
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingLimited-stage Small Cell Lung Cancer (LS-SCLC)China, France, United States, Spain, Taiwan, Korea, Republic of, Turkey, Italy, Netherlands, Georgia, Germany, Belgium, Poland, Romania
-
AstraZenecaCompletedChronic PainGermany, Sweden, United Kingdom
-
Aro BiotherapeuticsRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
BioRay Pharmaceutical Co., Ltd.Not yet recruitingAdvanced Solid MalignanciesChina
-
MediLink Therapeutics (Suzhou) Co., Ltd.RecruitingMetastatic Castration-resistant Prostate Cancer (mCRPC)China